|
|
||||||||
/TNF-
and IL-4/IL-5/IL-13, Respectively1






Departments of
*
Dermatology and
Pathology, Academic Medical Center, and
Department of AutoImmune Diseases, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, University of Amsterdam, Amsterdam, The Netherlands
| Abstract |
|---|
|
|
|---|
and IL-4 expression. To explore whether other cytokines are coproduced
along with IFN-
and IL-4, we investigated the secretion of a panel
of other cytokines (TNF-
, IL-5, IL-6, IL-10, and IL-13) by a large
number of these TCC. Upon analysis of 139 M.
leprae-responsive TCC, we observed a positive correlation in the
coproduction of IFN-
/TNF-
(r = 0.81), and
in that of IL-4/IL-5 (r = 0.83), IL-4/IL-13
(r = 0.80), and IL-5/IL-13
(r = 0.82). Polarized type 1-like TCC produced
dominantly IFN-
/TNF-
, and polarized type 2-like TCC predominantly
IL-4/IL-5/IL-13. Most type 0-like TCC produced both sets of cytokines.
In contrast, type 1- and type 2-like subsets of M.
leprae-nonresponsive TCC (n = 58) did not
show the same coexpression of these cytokines. Furthermore, when the
differential expression of a broad panel of cytokines by individual
M. leprae-responsive TCC is considered, it appeared that
additional phenotypes could be recognized. These results suggested that
distinct isotypes of type 1- and type 2-like T cells, based on the
secretion of a panel of cytokines, may reflect M.
leprae-specific characteristics. | Introduction |
|---|
|
|
|---|
, and
lymphotoxin are known to sustain CMI responses against intracellular
pathogen and DTH reactions, whereas Th2 or type 2 T cells secrete IL-4
and IL-5, favoring humoral immune responses. On the other hand, the
majority of T cells known as Th0 or type 0 T cells produce all
lymphokines that are associated with both the Th1 and Th2 subsets.
Leprosy is a dynamic disease model in which distinct
Mycobacterium leprae-responsive T cell subsets appear to
control the clinical and immunologic spectrum (3, 4, 5, 6). Type 1-like T
cells are associated with tuberculoid leprosy patients that are
characterized by strong M. leprae-specific CMI-DTH responses
restricting the growth of bacilli in the lesions (3, 4, 5). On the other
hand, type 2-like T cells are observed predominantly in lepromatous
leprosy patients that are characterized by strong humoral immune
responses in association with the absence of M.
leprae-specific T cell responses paralleling the dissemination of
infection (3, 4). Between the two polar forms of leprosy, the majority
of the patients are the immunologically unstable borderline patients
that are classified as borderline tuberculoid (BT), mid-borderline
(BB), or borderline lepromatous (BL). As a consequence, these patients
often experience acute immunologic changes in the form of reactions
during the course of the disease. To elucidate the mechanism of the
pathology of reactions, we undertook studies on the contribution of the
distinct T cell subsets in the lesional skin of these patients in the
form of a follow-up study (6). We observed that when borderline
patients experienced acute episodes of increased CMI-DTH responses
during treatment, known as reversal reaction (RR) (7, 8), the
IFN-
/IL-4 secretion profile of the skin-derived M.
leprae-responsive T cells shifted to a polarized type 1-like
phenotype. In the same study, we demonstrated, in concordance with the
results reported in recent literature, that irrespective of the
clinical status of the patient, a major subset of M.
leprae-responsive T cells have a type 0-like phenotype, producing
both IFN-
and IL-4 (6, 9).
It is now increasingly appreciated that besides IFN-
and IL-4, other
cytokines produced by T cells (TNF-
, IL-6, IL-10, and IL-13) also
regulate CMI-DTH and humoral immune responses (10, 11). Several lines
of evidence suggest that coproduction of various cytokines by type 1-
and/or type 2-like human T cell subsets is associated with the type of
disease, from which the T cells originate, and/or their Ag
specificities. In this respect, type 1-like Mycobacterium
tuberculosis-reactive TCC were found to coproduce predominantly
TNF-
and IL-10, and occasionally IL-5 (12), whereas type 1-like TCC
generated from psoriasis lesional skin produced little or no TNF-
and IL-10 (13). Coproduction of IL-4 and IL-6 was found in T cells
generated from synovial fluid of patients with rheumatoid arthritis
(14). Allergen-specific type 1- and type 2-like TCC did not differ in
respect to their TNF-
or IL-6 production (15), whereas other
investigators showed positive correlation of IL-10 production with
allergen-specific type 2-like T cells (16).
To date, simultaneous production of cytokines other than IFN-
and
IL-4 by M. leprae-responsive T cells from lesional skin was
studied with only limited number of M. leprae-reactive TCC
(4, 17), and to our knowledge no evaluations were conducted to
determine in parallel the extent of coproduction of a large panel of
cytokines. In particular, studies regarding the production of IL-13 by
skin-derived M. leprae-specific TCC have never been
reported. Since a large panel of M. leprae-responsive and
M. leprae-nonresponsive TCC was produced from the lesional
skin of borderline leprosy patients with distinct CMI-DTH status and
was classified on the basis of their IFN-
/IL-4 ratio (6), we
extended our studies by examining the simultaneous production of a
broad panel of cytokines (TNF-
, IL-5, IL-6, IL-10, and IL-13) by
these TCC. The cytokine secretion profile of both M.
leprae-responsive and M. leprae-nonresponsive TCC was
compared to elucidate the paradigm concerning the classification of T
cell subsets as well as to evaluate the extent of association of the
coproduction of these cytokines by TCC with the M. leprae
responsiveness.
| Materials and Methods |
|---|
|
|
|---|
Both M. leprae-responsive and M.
leprae-nonresponsive TCC used in this study were generated from
lesional skin biopsies of three untreated borderline leprosy patients
(one BT patient with RR (P6), one BB patient with RR (P7), and one BL
patient (P4)), and again from the lesions of these patients when they
(re)experienced an RR during treatment in the course of the disease.
The details of the methods of generation and phenotyping
(CD4+, CD8+, or TCR-
/
+) of
these TCC were described previously (6). Briefly, primary T cell lines
(TCL), spontaneously migrated from lesional skin biopsy specimen, were
expanded by mitogenic stimulation with 0.05% PHA (Difco, Detroit, MI)
in the presence of 3000-rad-irradiated allogenic feeder cells comprised
of PBMC from two unrelated donors, EBV-transformed B cells (JY) and
rIL-2 (a gift from Eurocetus, Amsterdam, The Netherlands). After
expansion, these TCL were analyzed for their responsiveness to M.
leprae using an Ag-induced stimulation assay (as described
earlier, 6). When the TCL were found M. leprae responsive,
rIL-2 was added to identical cultures for further promoting the
expansion of the M. leprae-responsive T cells. These
expanded T cells were then cloned by limiting dilution using a
protocol, as described previously (18). The individual TCC were further
expanded by mitogenic stimulation in the presence of an irradiated
allogenic feeder cell mixture, as described above, and screened for
their M. leprae responsiveness. In parallel, all TCC (both
M. leprae responsive and nonresponsive) were
stimulated for cytokine production, as described below.
In vitro stimulation of TCC for cytokine production
As described previously (6), the IFN-
/IL-4 secretion ratios
of the M. leprae-responsive TCC upon stimulation
with either M. leprae Ag or PMA/anti-CD3 did not differ,
whereas the absolute secretion levels of both cytokines by these TCC
stimulated by mitogen were higher. A similar trend of differences in
the secretion of other cytokines between mitogenic stimulation and
Ag-specific stimulation in the presence of autologous PBMC as APC was
found (data not shown). Moreover, some cytokines that are presently
investigated (particularly TNF-
and IL-6) were also produced by
irradiated PBMC in the presence of M. leprae Ags (data not
shown). Such basal secretion levels of cytokines by irradiated PBMC may
mask the actual secretion level of Ag produced by T cells. Most
importantly, we were interested in establishing the coexpression
profile of several cytokines by M. leprae-responsive as
compared with those M. leprae-nonresponsive TCC generated
from the same lesions. Therefore, the supernatants of TCC stimulated by
PMA/anti-CD3, according to the methods described elsewhere (6, 19),
have been used for measuring the cytokine secretion profiles. Briefly,
10 days after the last mitogenic stimulation with PHA (0.05%) and
allogenic feeder cells, T cells (105 cells/well) were
incubated with immobilized CD3 mAb (OKT3, 1 mg/ml) and PMA (1 ng/ml) in
a total volume of 200 µl/well in a flat-bottom 96-well plate. After
24 h, 100 µl of cell-free supernatants were harvested from each
well and stored at -80°C until tested. The remaining cultures were
subsequently cultured for an additional 16 h in the presence of
0.3 µCi/well [3H]thymidine to confirm stimulation.
Quantification of IFN-
, TNF-
, IL-4, IL-5, IL-6, IL-10, and
IL-13 in the supernatants of stimulated T cell clones
All cytokines were measured with specific sandwich ELISA, testing the serial dilutions of supernatants starting at a 1/10 dilution.
IFN-
.
The ELISA was performed as described before (20). Briefly, flat-bottom
EIA/RIA ELISA microtiter plates (Costar, Cambridge, MA) were coated for
3 h with a mouse anti-human capture mAb MD2 (Innogenetics,
Gent, Belgium) at 10 µg/ml in a 0.1 M carbonate buffer (pH 9.6, 50
µl/well) in a 37°C humidified atmosphere containing 5%
CO2. All subsequent incubation steps were in 50 µl
volumes and were followed by a washing step with PBS supplemented with
0.05% (v/v) Tween-20. The plates were washed twice and incubated for
1 h with PBS/3% BSA (37°C, 5% CO2) as a blocking
step. After washing, freshly thawed IFN-
-containing samples diluted
in PBS/3% BSA were then added and incubated overnight at 4°C. Plates
were washed, and biotinylated mAb MD1 was added for 2 h (37°C,
5% CO2). Thereafter, the plates were washed and incubated
with horseradish peroxidase-coupled streptavidin (Genzyme Corp.,
Cambridge, MA), 1/5000 diluted (according to the manufacturers
instructions) in PBS/3% BSA for 1 h (37°C, 5%
CO2), and washed, and the enzymatic activity was determined
with the substrate 1,2-phenylene-diamine (Fluka, Buchs, Switzerland)
with H2O2 (30%) in substrate buffer, pH 5.4.
The reaction was stopped by adding an equal volume of 1 M
H2SO4 to the wells. Plates were read at dual
wavelength of 490 and 405 nm in a micro plate reader (Bio-Rad,
Richmond, CA). Human IFN-
was used as a standard; the detection
limit for IFN-
was found to be at the detection level of 50
pg/ml.
IL-4 ELISA.
The assay was performed identical to the IFN-
ELISA, and has been
described before (21). For coating mAb CLB-IL-4/5 was used at 1
µg/ml, and for detection biotinylated mAb CLB-IL-4/1 was used at 1
µg/ml. Human IL-4 was used as a standard, and the detection limit was
40 pg/ml.
IL-5 ELISA.
The assay was performed identically to the IFN-
ELISA, with the
following exceptions (22): the IL-5-containing samples were incubated
for 1 h at 37°C, the incubation time of the biotinylated Ab was
1 h, and the horseradish peroxidase-coupled streptavidin was
diluted in PBS/3% BSA in the presence of 2% (v/v) milk and incubated
for 0.5 h. For coating mAb TRFK5 (PharMingen, San Diego, CA) was
used at 2 µg/ml, and for detection biotinylated JES1-5A10
(PharMingen) at 0.1 µg/ml. Human rlL-5 (Glaxo Institute for Molecular
Biology, Geneva, Switzerland) was used as a standard; the detection
limit was 20 pg/ml.
TNF-
ELISA.
We used the Pelikan compact human TNF-
ELISA kit (Central Laboratory
of the Netherlands Red Cross Blood Transfusion Service (CLB),
Amsterdam, the Netherlands). The detection limit was 8 pg/ml.
IL-13 ELISA. The ELISA was performed as described before (23). Flat-bottom microtiter plates (Nunc, Maxisorb) were coated overnight at 4°C with mouse anti-human capture mAb CLB-IL-13/3 at 1 µg/ml in 0.1 M carbonate buffer (pH 9.6, 100 µl/well). All subsequent incubations were in 100 µl volumes at room temperature. The plates were washed with PBS, 0.02% (v/v) Tween-20 and incubated for 30 min with PBS, containing 2% (v/v) milk as blocking step. After washing, biotinylated mAb CLB-IL-13/2 at 0.5 µg/ml was added together with the IL-13-containing samples diluted in high performance ELISA buffer (CLB) for 2 h. Thereafter, the plates were washed and incubated with polystreptavidin-horseradish peroxidase (PolyHRP; CLB), 1/10,000 diluted (according to the manufacturers instruction) in PBS containing 2% (v/v) milk for 0.5 h, washed, and developed with a solution of 100 µg/ml of 3,5,3',5'-tetramethybenzidine (Merck, Darmstadt, Germany) with 0.003% (v/v) H2O2 in 0.11 M sodium acetate, pH 5.5 (100 µl/well). The reaction was stopped by adding an equal volume of 1 M H2SO4 to the wells. Plates were read at 450 nm in a Titertek Multiskan reader Labsystems Multiskan (Multisoft, Helsinki, Finland). Background absorbance at 540 nm was subtracted. Human rIL-13 (Pretotech, London, U.K.) was used as a standard. The detection limit was 8 pg/ml.
IL-6 ELISA. Procedures were identical to the IL-13 ELISA, except that the blocking step was eliminated (24). For coating mAb CLB-IL-6/16 was used at 1 µg/ml. Affinity-purified polyclonal sheep anti-IL-6 was used for detection at 0.25 µg/ml. PBMC-derived IL-6, calibrated to human rIL-6 (25), was used as a standard. The detection limit was 2 pg/ml.
IL-10 ELISA. The assay was performed identical to the IL-13 ELISA, except that the blocking step was omitted (26). For coating mAb B-N10 was used at 0.5 µg/ml in PBS, and for detection biotinylated mAb anti-IL-10 (B-T10) was used at 0.125 µg/ml. Human rIL-10 was used as a standard. The detection limit was 15 pg/ml.
Statistics
Spearman correlation coefficients (r) of coproduction of pairs of cytokines were calculated. Comparison of the production level of a cytokine between subsets of TCC was performed using the Mann-Whitney test. p values < 0.05 were considered significant.
| Results |
|---|
|
|
|---|
Table I
shows the origin of 139
M. leprae-responsive TCC and their phenotypes according to
their IFN-
and IL-4 production levels upon stimulation with PMA plus
anti-CD3, as previously described (6). The absolute values of
IFN-
and IL-4 production by these TCC are illustrated in Figure 1
. One hundred twenty-eight of these TCC
were CD4+, seven were CD8+ and/or
TCR-
/
+, and four were not phenotyped. The TCC with a
type 0-like phenotype (IFN-
/IL-4 ratio ranging from 0.4 to 20) were
generated from all lesions, irrespective of the immune status of the
patient. Type 1-like TCC (IFN-
/IL-4 ratio > 20) predominantly
originated from the lesional skin of patients, characterized by high
levels of CMI-DTH against M. leprae, and were most
prominently seen in the lesions from those patients (re)experiencing an
RR during treatment. Type 2-like TCC (IFN-
/IL-4 ratio < 0.4)
dominated in the lesion of an untreated patient (P4) with strong
humoral immune responses in the absence of CMI-DTH responses against
M. leprae. As described previously (6), it appeared that the
polarized cytokine profile of these M. leprae-responsive TCC
reflected the local immunopathologic status of the borderline leprosy
patient.
|
|
, IL-4,
TNF-
, IL-5, IL-6, IL-10, and IL-13 by M.
leprae-responsive TCC
The production of TNF-
, IL-5, IL-6, IL-10, and IL-13 by all
M. leprae-responsive TCC was measured by ELISA in the same
supernatants that were used for IFN-
and IL-4 detection. Most TCC
did not produce IL-6 above detection level (<15 pg/ml), and
coproduction of IL-6 with other cytokines was therefore not further
analyzed. Spearman correlation coefficients
(r) of coproduction of cytokines are presented
in Figure 2
and summarized in Table II
. The production of IFN-
and that of
TNF-
was strongly correlated (r = 0.81, Fig. 2
A), whereas the production of both of these
cytokines did not correlate with the production of either IL-4
(r = 0.10, r = 0.15,
respectively) or IL-5 (r = 0.09,
r = 0.17, respectively), and correlated weakly with
IL-13 (r = 0.34, r = 0.41,
respectively). On the other hand, the production of IL-4 strongly
correlated with the production of IL-5 (r =
0.83, Fig. 2
B) and IL-13 (r =
0.80, Fig. 2
C). In addition, the production of IL-5
and that of IL-13 strongly correlated (r = 0.82,
Fig. 2
D). The production of IL-10 weakly correlated
with the production of all other cytokines: e.g., IFN-
(r = 0.40), TNF-
(r =
0.61), IL-4 (r = 0.55), IL-5
(r = 0.61), and IL-13 (r
= 0, 63). Figure 2
, E and F, illustrates two
representative examples of the production of IL-10 in conjunction with
IFN-
and IL-4, respectively.
|
|
Since the production of IFN-
/TNF-
, and the production of
IL-4/IL-5, IL-4/IL-13, and IL-5/IL-13 by M.
leprae-responsive TCC were positively correlated, we investigated
whether these cytokines were differentially produced by the
predesignated type 1- and type 2-like T cell subsets. Indeed, such
differences in the coproduction of cytokines with either IFN-
or
IL-4 can be further seen when the mean cytokine secretions by these
type 1- and type 2-like TCC were calculated (Table III
). Additionally, the absolute values
of TNF-
(p < 0.004), IL-5
(p = 0.001), and IL-13
(p < 0.001) are significantly different
between type 1-like (n = 57) and type 2-like
(n = 17) TCC. In spite of the fact that the
production of IL-10 was found to correlate weakly with the production
levels of either IFN-
or IL-4, type 2-like T cells produce
significantly more IL-10 (p = 0.008).
|
/IL-4 ratio
187, n = 9)
dominantly coproduced high levels of IFN-
and TNF-
, but with only
low amounts of IL-13. Only one TCC (78.13) produced high amounts of
IL-13. On the other hand, polarized type 2-like TCC (IFN-
/IL-4
ratio
0.25, n = 9) dominantly coproduced high
levels of IL-4, IL-5, and IL-13. In contrast with the significantly
different production level of IL-10 between type 1- and type 2-like T
cell subsets, as presented in Table III
or IL-4, as was presented in
Table II
|
We found that two main sets of cytokines are coproduced by
M. leprae-responsive TCC: IFN-
/TNF-
prominently by
type 1-like T cells and IL-4/IL-5/IL-13 prominently by type 2-like T
cells. TCC with the type 0-like phenotype (n =
65) were found to produce both sets of cytokines (data not shown).
However, when analyzing quantitatively the cytokine secretion profile
of individual TCC, a correlated production of IL-4/IL-5/IL-13 by type
1- and type 0-like TCC was not always observed. We considered TCC to be
low producers of IL-4, IL-5, or IL-13 when the production of IL-4 or
IL-5 was below 1 ng/ml, and the production of IL-13 below 10 ng/ml,
respectively. Following such criteria, a subset of type 1- and type
0-like TCC producing either high levels of IL-4 and IL-5, IL-5 and
IL-13, IL-4 and IL-13, or high levels of any of those cytokines alone
was identified (Table V
). Another
exception can also be seen in that one type 2-like TCC (74.21) produced
high amounts of IL-4 and IL-5, but low levels of IL-13 (see Table IV
).
|
To further substantiate the specific characteristic of
M. leprae-responsive T cell subsets, we also investigated in
parallel the coproduction of the same panel of cytokines for a
number of M. leprae-nonresponsive TCC
(n = 58) that were generated from the same
lesions as an internal control. According to their IFN-
and IL-4
production levels, type 1-like (n = 16), type
0-like (n = 25), and type 2-like
(n = 17) TCC were included. Within this panel, a
subset of TCC was found to produce IL-6. In contrast with the M.
leprae-responsive TCC, strongly correlated production of
IFN-
/TNF-
, IL-4/IL-5, and IL-4/IL-13 by these TCC was not
observed (data not shown). Only the IL-5 and IL-13 expression were
found to be related (r = 0.80). The absence in
coproduction of IFN-
/TNF-
, and IL-4/IL-13 can be further seen
when the mean cytokine secretions by the predesignated type 1- and type
2-like M. leprae-nonresponsive TCC were calculated (Table VI
). The absolute production levels of
TNF-
(p = 0.22) and IL-13
(p = 0.09) did not significantly differ between
those two subsets of TCC. However, in spite of weak correlated
production of IL-5, IL-6, and IL-10 with the production of IL-4
(r = 0.65, r = 0.39, and
r = 0.53, respectively), these cytokines were found to
be significantly more produced by type 2-like T cells.
|
| Discussion |
|---|
|
|
|---|
or
IL-4, respectively. This restricted cytokine secretion profile,
however, may not reflect the complex regulatory role of T cells in
vivo. Therefore, we undertook to investigate the secretion profile of a
broad panel of cytokines (IFN-
, TNF-
, IL-4, IL-5, IL-6, IL-10,
and IL-13) by a large panel of TCC with specificity toward M.
leprae. These TCC were derived from the lesional skin of
borderline leprosy patients with changing immune status that were
investigated in a follow-up study (6). As previously described, based
on their IFN-
/IL-4 secretion profile, the polarized type 1- or type
2-like phenotype of the M. leprae-responsive TCC reflected
the local immune status of the patient from which they were generated.
In the same study, a large number of type 1-, type 0-, or type 2-like
M. leprae-nonresponsive TCC was also generated in parallel
from the same lesions and offered the opportunity to compare the
cytokine secretion profiles of these TCC with those of M.
leprae-responsive TCC under the same experimental conditions. By
doing so, the specific characteristics of the M.
leprae-responsive T cell subsets can be better understood.
Despite the similarities in functional properties of TNF-
with
IFN-
(27), and of IL-6, IL-10, and IL-13 with IL-4 (28, 29, 30, 31, 32), the
production of these cytokines is not found to be restricted
predominantly to either the type 1- or type 2-like human T cell
subsets, respectively (2, 33, 34). In the present study, we showed that
the production of IFN-
/TNF-
, and IL-4/IL-5/IL-13 by M.
leprae-responsive TCC was positively correlated. Consequently, the
production levels of TNF-
, IL-5, and IL-13 were found to differ
significantly between the type 1- and type 2-like T cell subset. Since
type 1- and type 2-like M. leprae-nonresponsive TCC did not
differ in their production levels of TNF-
and IL-13, our findings
suggest that coproduction of IFN-
/TNF-
vs IL-4/IL-13 may be
characteristic for T cells with reactivity to M. leprae.
Coproduction of IL-5 and IL-4 has already been shown for human T cells,
particularly with the type 2-like phenotype, with varying Ag
specificities (1, 2). Since TNF-
is also produced by M.
tuberculosis-responsive type 1-like TCC (12), coproduction of
these proinflammatory cytokines may be characteristic for T cells in
mycobacterial infections in general. Indeed, type 1-like TCC from
psoriasis lesional skin produced little or no TNF-
(13), whereas
allergen-specific type 1- as well as type 2-like TCC were found to
produce similar amounts of TNF-
(15). To date, other studies failed
to show that production of IL-13 is associated with a type 2-like
phenotype of human T cells. In this respect, correlated production of
IL-4 and IL-13 was found to be absent in TCC with specificity to
allergen (34). Additionally, similar production levels of IL-13 were
found for type 1-, type 0-, and type 2-like TCC with varying Ag
specificities (35) (Dr. Eddy A. Wierenga, personal communication).
It should be noted that TNF-
was produced predominantly by the type
1-like M. leprae-responsive T cells. These T cells were
generated predominantly from the lesional skin of borderline leprosy
patients undergoing RR characterized by CMI-DTH responses against
M. leprae. (6). Furthermore, such type 1-like Ag-responsive
TCC were also generated from BT patients with high Ag-specific CMI-DTH
responses (6). In the context of the role of the T cell cytokines in
leprosy, it is suggestive that TNF-
may contribute to the
elimination of bacilli (27), as well as the granuloma formation (36)
and tissue damage in the lesions. Interestingly, TNF-
has also been
described as an important cytokine in mediating myelin and
oligodendrocyte damage in vitro (37). Since most polarized type 1-like
TCC originated from the skin lesions of patients with RR (as presented
in Table I
), it is suggestive that this cytokine is crucial to cause
nerve damage in those patients. Such assumption is compatible with the
observation by other investigators that showed increased levels of
TNF-
in the lesions with RR (38, 39). On the other hand, IL-13 was
coproduced dominantly by type 2-like M. leprae-responsive
TCC that were generated predominantly from a borderline lepromatous
leprosy (BL) patient characterized by the lack of CMI-DTH responses to
M. leprae, but with significant humoral immunity (6). Since
IL-13 shares with IL-4 the functional properties of inhibiting CMI
responses by the inactivation of monocyte functions (31, 40), as well
as favoring humoral immunity by the activation of B cells (40), our
findings implied that IL-13 may contribute to high Ab serum levels and
unrestricted replication of bacilli in the lesion of such patients.
Further studies are required to more fully understand the role of T
cell-derived TNF-
and IL-13 in the immunopathologic spectrum of
leprosy.
An interesting finding of the present study is that type 1- and type 0-like TCC did not always show coproduction of IL-4/IL-5/IL-13. These data may support the hypothesis that cytokine-producing T cells display a spectrum of cytokine profiles, of which the polarized type 1- and type 2-like T cells represent the two possible extremes (41). A preliminary analysis of our data indicates that most of these TCC showing the variable spectrum of cytokine secretion profiles could be generated from the lesions of borderline leprosy patients irrespective of their clinical status. However, these indeterminate TCC, depending on their coexpressions of particular cytokine profiles, might be pivotal in the pathophysiology of the disease process by interacting with other type 1- or type 2-like T cell subsets in the microenvironment of the granuloma. Such assumption, nevertheless, should be taken with caution until a detailed analysis of the cytokine secretion profile of these TCC in relation to the disease activities of the individual patient has been evaluated. At present it should be emphasized that the significance of these indeterminate subsets of TCC in respect to the pathology of leprosy could not be drawn from this study.
In this study, we also showed that IL-10 was produced predominantly by
type 2-like M. leprae-responsive T cells. However, a weak
correlation between the production of IL-10 and other type 2-like
cytokines, as determined in the whole panel of TCC, was found. This may
be explained by the fact that a subset of type 1-like M.
leprae-responsive TCC produced IL-10 with varying secretion
levels. It is interesting to note that the type 1-like M.
leprae-responsive TCC, but not the type 1-like M.
leprae-nonresponsive TCC, could be divided into a subset of
IFN-
+/TNF-
+/IL-10- type
1-like TCC (n = 35; IL-10 production below
detection level 0.2 ng/ml) and a subset of
IFN-
+/TNF-
+/IL-10+ type
1-like TCC (n = 35; varying production of IL-10
between 0.2 and 56.3 ng/ml). These data correlate well with other
studies that showed that human type 1-, type 0-, and type 2-like T
cells have the capacity to produce IL-10 upon activation (12, 33, 42),
whereas highest mean levels of IL-10 were synthesized by Th0- and
Th2-like TCC (42). Our data may support the idea that IL-10, by
down-regulating through monocytes the Ag-induced proliferation and
cytokine production of Th1 as well as Th2 cells (33), may be involved
in dampening both ongoing type 1- and type 2-like Ag-driven immune
responses. Recent evidence for such a regulatory role of IL-10 in
mycobacterial infection came from a study that shows that within the
antimycobacterial response of transgenic mice that secrete IL-10 only
from the T cell compartment, IL-10 overrides the antimycobacterial
effects of IFN-
on macrophages infected with Calmette-Guerin
bacillus (Mycobacterium bovis) (43).
M. leprae-responsive TCC may be characterized further by
minimal IL-6 production, irrespective of the secretion profile of other
cytokines. This finding is compatible with other studies showing that
M. leprae-responsive TCL (44) and TCC (4)
generated from leprosy patients do not produce IL-6. Although
production of IL-6 by T cells is generally regarded to be minimal, the
production of this cytokine by T cells has been reported in rheumatoid
arthritis (14), and was found to be produced predominantly by the type
2-like M. leprae-nonresponsive TCC investigated in the
present study. Since additionally M. tuberculosis-specific T
cells lacked the expression of IL-6 mRNA (45), it is suggestive that
the absence of IL-6 production is another characteristic for
Mycobacterium-responsive T cells in general. The
implications of the absence of IL-6 production by M.
leprae-responsive T cells cannot be drawn from this study.
In conclusion, it appears that the classification of T cell subsets on
the basis of cytokine profiles may be regarded as pathogen specific. In
respect to the pathology of leprosy, the balanced production of
IFN-
/TNF-
vs IL-4/IL-5/IL-13 by type 1- and type 2-like M.
leprae-responsive T cells, respectively, may play a dominant role
in the T cell-mediated immune responses.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Pranab K. Das, Department of Pathology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam Z-O, The Netherlands. E-mail address: ![]()
3 Abbreviations used in this paper: CMI, cell-mediated immunity; BL, borderline lepromatous; BT, borderline tuberculoid; BB, mid-borderline; DTH, delayed-type hypersensitivity; RR, reversal reaction; TCC, T cell clone; TCL, T cell line. ![]()
Received for publication July 17, 1997. Accepted for publication November 4, 1997.
| References |
|---|
|
|
|---|
) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reaction. Clin. Exp. Immunol. 99:196.[Medline]
This article has been cited by other articles:
![]() |
M. Saeftel, M. Arndt, S. Specht, L. Volkmann, and A. Hoerauf Synergism of Gamma Interferon and Interleukin-5 in the Control of Murine Filariasis Infect. Immun., December 1, 2003; 71(12): 6978 - 6985. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J. de Boer, A. C. van der Wal, M. A. Houtkamp, J. M. Ossewaarde, P. Teeling, and A. E. Becker Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae Cardiovasc Res, December 1, 2000; 48(3): 402 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marchant, T. Goetghebuer, M. O. Ota, I. Wolfe, S. J. Ceesay, D. De Groote, T. Corrah, S. Bennett, J. Wheeler, K. Huygen, et al. Newborns Develop a Th1-Type Immune Response to Mycobacterium bovis Bacillus Calmette-Guerin Vaccination J. Immunol., August 15, 1999; 163(4): 2249 - 2255. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |